MedTrace Logo

Patterns of Treatment and Outcome of Palbociclib Plus Endocrine Therapy

NCT04524728 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 191

Last updated 2020-08-24

No results posted yet for this study

Summary

This is a multicentre real-world experience aimed at verifying the outcome of palbociclib plus ET in an unselected population of MBC patients. The primary endpoint is the clinical benefit rate (CBR); secondary aims are the median PFS (mPFS), overall survival (OS) and safety.

Conditions

  • Breast
  • Neoplasm Malignant
  • Female

Interventions

DRUG

Palbociclib

tablets

DRUG

Letrozole 2.5mg

tablets

DRUG

Fulvestrant

intramuscolar injections

Sponsors & Collaborators

  • Istituti Clinici Scientifici Maugeri SpA

    lead OTHER

Principal Investigators

  • Raffaella Palumbo, MD, PhD · ICS Maugeri, IRCCS, Department of Medical Oncology, Pavia, italy

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2019-04-30
Completion
2020-06-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04524728 on ClinicalTrials.gov